HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cost-effectiveness of integrated collaborative care for comorbid major depression in patients with cancer.

AbstractOBJECTIVES:
Comorbid major depression is associated with reduced quality of life and greater use of healthcare resources. A recent randomised trial (SMaRT, Symptom Management Research Trials, Oncology-2) found that a collaborative care treatment programme (Depression Care for People with Cancer, DCPC) was highly effective in treating depression in patients with cancer. This study aims to estimate the cost-effectiveness of DCPC compared with usual care from a health service perspective.
METHODS:
Costs were estimated using UK national unit cost estimates and health outcomes measured using quality-adjusted life-years (QALYs). Incremental cost-effectiveness of DCPC compared with usual care was calculated and scenario analyses performed to test alternative assumptions on costs and missing data. Uncertainty was characterised using cost-effectiveness acceptability curves. The probability of DCPC being cost-effective was determined using the UK National Institute for Health and Care Excellence's (NICE) cost-effectiveness threshold range of £ 20,000 to £ 30,000 per QALY gained.
RESULTS:
DCPC cost on average £ 631 more than usual care per patient, and resulted in a mean gain of 0.066 QALYs, yielding an incremental cost-effectiveness ratio of £ 9549 per QALY. The probability of DCPC being cost-effective was 0.9 or greater at cost-effectiveness thresholds above £ 20,000 per QALY for the base case and scenario analyses.
CONCLUSIONS:
Compared with usual care, DCPC is likely to be cost-effective at the current thresholds used by NICE. This study adds to the weight of evidence that collaborative care treatment models are cost-effective for depression, and provides new evidence regarding their use in specialist medical settings.
AuthorsA Duarte, J Walker, S Walker, G Richardson, C Holm Hansen, P Martin, G Murray, M Sculpher, M Sharpe
JournalJournal of psychosomatic research (J Psychosom Res) Vol. 79 Issue 6 Pg. 465-70 (Dec 2015) ISSN: 1879-1360 [Electronic] England
PMID26652589 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.
Topics
  • Adult
  • Aged
  • Comorbidity
  • Cost-Benefit Analysis
  • Delivery of Health Care, Integrated (economics)
  • Depression (economics, therapy)
  • Depressive Disorder, Major (economics, therapy)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasms (psychology)
  • Patient Care Team
  • Quality of Life
  • Quality-Adjusted Life Years

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: